连续注射低剂量白细胞介素-2 可改善慢性自发性荨麻疹患者的症状和疾病控制。
Consecutive injections of low-dose interleukin-2 improve symptoms and disease control in patients with chronic spontaneous urticaria.
机构信息
Department of Dermatology, Hunan Clinical Medicine Research Center for Major Skin Diseases and Skin Health, The Second Xiangya Hospital of Central South University, 139 Middle Renmin Road, Changsha, Hunan 410011, China.
Department of Dermatology, Hunan Clinical Medicine Research Center for Major Skin Diseases and Skin Health, The Second Xiangya Hospital of Central South University, 139 Middle Renmin Road, Changsha, Hunan 410011, China.; Department of Dermatology, The First people's Hospital of Changde City, Changde, Hunan 415003, China.
出版信息
Clin Immunol. 2023 Feb;247:109247. doi: 10.1016/j.clim.2023.109247. Epub 2023 Jan 29.
PURPOSE
To describe the effectiveness and tolerability of low-dose interleukin (IL)-2 in treating patients with chronic spontaneous urticaria (CSU) refractory to H-antihistamines.
METHODS
This retrospective study included CSU patients who received treatment with at least one cycle of IL-2, injected intramuscularly at a dose of 1.0 million international units daily for 7 consecutive days, after failing treatment with H-antihistamines. Patients were followed up for ≥12 weeks.
RESULTS
Of the 15 patients, 7 (46.7%) and 11 (73.3%) achieved complete response at Week 2 and Week 12, respectively. The mean change of urticaria control test (UCT) and weekly urticaria activity score (UAS7) from baseline was 6.6 (95% CI, 4.2 to 8.9) and - 16.9 (95% CI, -24.0 to -9.8), respectively, at Week 12. Local injection-site reactions were the most common adverse events. No serious adverse events were reported.
CONCLUSION
Low-dose IL-2 treatment improves symptoms and disease control for CSU patients refractory to H-antihistamines.
目的
描述低剂量白细胞介素（IL）-2 治疗对 H 抗组胺药物难治的慢性自发性荨麻疹（CSU）患者的有效性和耐受性。
方法
本回顾性研究纳入了接受至少一个周期 IL-2 治疗的 CSU 患者，在 H 抗组胺药物治疗失败后，患者接受每日 100 万国际单位的肌肉内注射，连续 7 天。对患者进行了≥12 周的随访。
结果
在 15 名患者中，分别有 7 名（46.7%）和 11 名（73.3%）在第 2 周和第 12 周时达到完全缓解。第 12 周时，荨麻疹控制测试（UCT）和每周荨麻疹活动评分（UAS7）自基线的平均变化分别为 6.6（95%置信区间，4.2 至 8.9）和-16.9（95%置信区间，-24.0 至-9.8）。最常见的不良反应是局部注射部位反应。未报告严重不良事件。
结论
低剂量 IL-2 治疗可改善对 H 抗组胺药物难治的 CSU 患者的症状和疾病控制。
Zotero 插件